Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
Haematologica
.
2020 Nov 1;105(11):2664-2666.
doi: 10.3324/haematol.2019.242529.
Authors
Guillaume Manson
1
,
Pauline Brice
2
,
Charles Herbaux
3
,
Kamal Bouabdallah
4
,
Chloé Antier
5
,
Florence Poizeau
6
,
Laurent Dercle
7
,
Roch Houot
1
Affiliations
1
Department of Hematology, University Hospital of Rennes, Rennes, France.
2
Department of Hematology, Saint-Louis Hospital, AP-HP, Paris, France.
3
Department of Hematology, University Hospital of Lille, Lille, France.
4
Department of Hematology, University Hospital of Bordeaux, Bordeaux, France.
5
Department of Hematology, Nantes University Hospital, Nantes, France.
6
Department of Dermatology, Rennes University Hospital, Rennes, France.
7
Department of Radiology, Columbia University Medical Center, New York, New York, USA.
PMID:
33131257
PMCID:
PMC7604630
DOI:
10.3324/haematol.2019.242529
No abstract available
Publication types
Letter
MeSH terms
Antineoplastic Agents, Immunological* / adverse effects
Hodgkin Disease* / drug therapy
Humans
Programmed Cell Death 1 Receptor
Substances
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor